During the past decade, Sapporo Higashi Tokushukai Hospital conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 18 clinical trials were completed, i.e. on average, 40.9% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 17 clinical trials were completed. i.e. 81% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Sapporo Higashi Tokushukai Hospital" #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "Shire" with 5 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "Pfizer" with 4 trials sponsored and "Galapagos NV" with 4 trials sponsored. Other sponsors include 19 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sapporo Higashi Tokushukai Hospital" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Boston Scientific Japan K.K." with 1 trials as a collaborator and "Chiltern International Inc." with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Sapporo Higashi Tokushukai Hospital" are "Crohn's Disease" (12 trials), "Ulcerative Colitis" (12 trials), "Colitis, Ulcerative" (5 trials), "Coronary Artery Disease" (3 trials) and "Atrial Fibrillation" (2 trials). Many other conditions were trialed in "Sapporo Higashi Tokushukai Hospital" in a lesser frequency.

Most popular intervention types in "Sapporo Higashi Tokushukai Hospital" are "Drug" (35 trials), "Device" (7 trials), "Other" (6 trials), "Biological" (4 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (21 trials), "Guselkumab" (5 trials), "Filgotinib" (4 trials), "Mirikizumab" (4 trials) and "Ontamalimab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Sapporo Higashi Tokushukai Hospital" are 44 trials for "All" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Sapporo Higashi Tokushukai Hospital". undefined are not yet recruiting, 14 are recruiting, 12 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 13 completed trials in Sapporo Higashi Tokushukai Hospital, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Sapporo Higashi Tokushukai Hospital, 0 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 9 trials that are defined as “Not Applicable".